Ex­elix­is, Bris­tol-My­ers mount piv­otal study of Cabo/Op­di­vo com­bo for front­line kid­ney can­cer

Fouad Namouni, Bris­tol-My­ers Squibb

Just days af­ter re­view­ing a promis­ing start com­bin­ing Bris­tol-My­ers Squibb’s check­point in­hibitor Op­di­vo (nivolum­ab) with Cabome­tyx (cabozan­ti­nib), Ex­elix­is is rolling out a late-stage part­ner­ship that will take the com­bo in­to a piv­otal Phase III study as a front­line ther­a­py for kid­ney can­cer. And not sat­is­fied with the one check­point tie-up, the South San Fran­cis­co-based biotech al­so an­nounced a deal this morn­ing to col­lab­o­rate with Roche on a com­bi­na­tion of its drug Tecen­triq (ate­zolizum­ab) and cabo.

Ex­elix­is $EX­EL and Bris­tol-My­ers $BMY are split­ting the costs on their Phase III pro­gram, which will ex­plore the com­bo, ei­ther alone or with Yer­voy (ip­il­i­mum­ab), in kid­ney can­cer as well as blad­der can­cer, he­pa­to­cel­lu­lar car­ci­no­ma and pos­si­bly oth­er tu­mor types. The ear­ly stage work was done un­der an agree­ment with the NCI’s Can­cer Ther­a­py Eval­u­a­tion Pro­gram. This new pact marks Ex­elix­is’ and Bris­tol-My­ers’ first R&D col­lab­o­ra­tion in I/O.

Ex­elix­is shares jump 6% on the news.

Ten days ago Ex­elix­is un­veiled the first snap­shot of ef­fi­ca­cy da­ta for the dou­ble and triple com­bo in gen­i­touri­nary tu­mors.

In­ves­ti­ga­tors con­clud­ed:

Among the 43 pa­tients who were evalu­able for re­sponse, the ob­jec­tive re­sponse rate (ORR) for all tu­mor types was 30 per­cent (38 per­cent for the dou­blet dos­ing sched­ule and 18 per­cent for the triplet dos­ing sched­ule), with a 7 per­cent com­plete re­sponse (CR) rate and a 23 per­cent par­tial re­sponse (PR) rate. Sta­ble dis­ease (SD) was re­port­ed in 56 per­cent of pa­tients. The ORR for pa­tients with mUC was 38 per­cent, and 2 of 16 pa­tients achieved a CR, while 2 pa­tients with squa­mous cell car­ci­no­ma of the blad­der had ob­jec­tive re­spons­es (1 CR and 1 PR). In the mUC co­hort, 15 of 16 pa­tients had a CR, PR or SD as their best re­sponse.

“Com­bin­ing our Im­muno-On­col­o­gy port­fo­lio with promis­ing agents which tar­get dif­fer­ent and com­ple­men­tary path­ways is a key com­po­nent of our strat­e­gy to im­prove treat­ment out­comes for pa­tients,” said Fouad Namouni, MD, head of De­vel­op­ment, On­col­o­gy, Bris­tol-My­ers Squibb.

Bris­tol-My­ers — the one-time leader in check­point in­hibitors — is con­tin­u­ing to dou­ble down on Op­di­vo af­ter an em­bar­rass­ing se­ries of set­backs in lung can­cer bad­ly dent­ed its share price.

Leerink’s Michael Schmidt gave the deal a quick thumbs up, hap­py to see Ex­elix­is take a shot at mov­ing to front­line use.

This is pos­i­tive news since these col­lab­o­ra­tions could po­ten­tial­ly sig­nif­i­cant­ly ex­pand Cabome­tyx com­mer­cial po­ten­tial be­yond 2nd lien RCC, while lim­it­ing ad­di­tion­al in­cre­men­tal R&D spend which is in-line with mgmt.’s busi­ness strat­e­gy. While some of the Cabome­tyx opp’ty be­yond the cur­rent­ly ap­proved in­di­ca­tion in 2nd line RCC is re­flect­ed in our mod­el and val­u­a­tion, the scope of these col­lab­o­ra­tions ex­ceeds our ex­pec­ta­tions and could po­ten­tial­ly in­crease the reg­u­la­to­ry and com­mer­cial prob­a­bil­i­ty-of-suc­cess for Cabome­tyx in 1st line RCC. Our es­ti­mates are un­der re­view.

Ex­elix­is is al­so spon­sor­ing a Phase Ib study that pairs cabo with Tecen­triq in fight­ing sol­id tu­mors. With en­roll­ment planned to be­gin in the mid­dle of this year, in­ves­ti­ga­tors have a shot at lat­er open­ing up four treat­ment co­horts: one for pre­vi­ous­ly un­treat­ed ad­vanced clear cell re­nal cell car­ci­no­ma and three co­horts of urothe­lial car­ci­no­ma, in­clud­ing plat­inum el­i­gi­ble first-line pa­tients, first- or sec­ond-line plat­inum in­el­i­gi­ble pa­tients and pa­tients pre­vi­ous­ly treat­ed with plat­inum-con­tain­ing chemother­a­py.

The da­ta from these stud­ies can be made avail­able to Ex­elix­is’ part­ners, Ipsen and Take­da, for their own de­vel­op­ment ini­tia­tives, pro­vid­ed they opt in. So far though on­ly Ipsen has signed up.

“Peo­ple with ad­vanced gen­i­toruri­nary ma­lig­nan­cies are in need of ad­di­tion­al treat­ment op­tions that can im­prove clin­i­cal out­comes,” said Suman­ta Ku­mar Pal, MD, co-di­rec­tor, Kid­ney Can­cer Pro­gram at City of Hope, and prin­ci­pal in­ves­ti­ga­tor in the study. “The com­bined ap­proach of ty­ro­sine ki­nase in­hi­bi­tion with cabozan­ti­nib along­side im­mune-check­point in­hi­bi­tion has al­ready shown promise in an ear­ly phase 1 clin­i­cal tri­al. We look for­ward to fur­ther ex­am­in­ing this po­ten­tial with cabozan­ti­nib plus ate­zolizum­ab to treat a range of gen­i­touri­nary and oth­er tu­mors.”

A fa­vorite in Alex­ion’s C-suite is leav­ing, and some mighty sur­prised an­a­lysts aren’t the least bit hap­py about it

Analysts hate to lose a biotech CFO they’ve come to trust and admire — especially if they’re being blindsided by a surprise exit.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

David Grainger [file photo]

'Dis­con­nect the bas­tard­s' — one biotech's plan to break can­cer cell­s' uni­fied de­fens­es

Chemotherapy and radiotherapy are the current gladiators of cancer treatment, but they come with well-known limitations and side-effects. The emergence of immunotherapy — a ferocious new titan in oncologist’s toolbox — takes the brakes off the immune system to kill cancer cells with remarkable success in some cases, but the approach is not always effective. What makes certain forms of cancer so resilient? Scientists may have finally pieced together a tantalizing piece of the puzzle, and a new biotech is banking on a new approach to fill the gap.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

While No­var­tis ban­ish­es Zol­gens­ma scan­dal scars — Bio­gen goes on a Spin­raza 'of­fen­sive'

While Novartis painstakingly works to mop up the stench of the data manipulation scandal associated with its expensive gene therapy for spinal muscular atrophy (SMA) Zolgensma— rival Biogen is attempting to expand the use of its SMA therapy, Spinraza. 

The US drugmaker $BIIB secured US approval for Spinraza for use in the often fatal genetic disease in 2016. The approval covered a broad range of patients with infantile-onset (most likely to develop Type 1) SMA. 

Jason Kelly. Mike Blake/Reuters via Adobe

Eye­ing big ther­a­peu­tic push, Gink­go bags $290M to build a cell pro­gram­ming em­pire

Ginkgo Bioworks is on a roll. Days after publicizing a plan to nurture new startups via partnerships with accelerators Y Combinator and Petri, the Boston biotech says it has raised another $290 million for its cell programming platform to reach further and wider.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Speak­er Nan­cy Pelosi to un­veil bill for fed­er­al­ly ne­go­ti­at­ed drug prices

After months of buzz from both sides of the aisle, Speaker Nancy Pelosi will today introduce her plan to allow the federal government to negotiate prices for 250 prescription drugs, setting up a showdown with a pharmaceutical industry working overtime to prevent it.

The need to limit drug prices is a rare point of agreement between President Trump and Democrats, although the president has yet to comment on the proposal and will likely face pressure to back a more conservative option or no bill at all. Republican Senator Chuck Grassley is reportedly lobbying his fellow party members on a more modest proposal he negotiated with Democratic Senator Ron Wyden in July.

Jeff Kindler's Cen­trex­ion re­news bid to make pub­lic de­but

Jeffrey Kindler’s plan to take his biotech — which is developing a slate of non-opioid painkillers — public, is back on.

The Boston based company, led by former Pfizer $PFE chief Kindler, originally contemplated a $70 million to $80 million IPO last year— but eventually postponed that strategy. On Wednesday, the company revived its bid to make a public debut in a filing with the SEC — although no pricing details were disclosed.

Zachary Hornby. Boundless

'A fourth rev­o­lu­tion in can­cer ther­a­pies': ARCH-backed Bound­less Bio flash­es big check, makes big­ger promis­es in de­but

It was the cellular equivalent of opening your car door and finding an active, roaring engine in the driver seat.

Scientists learned strands of DNA could occasionally appear outside of its traditional home in the nucleus in the 1970s, when they appeared as little, innocuous circles on microscopes; inexplicable but apparently innate. But not until UC San Diego’s Paul Mischel published his first study in Science in 2014 did researchers realize these circles were not only active but potentially overactive and driving some cancer tumors’ superhuman growth.

It’s fi­nal­ly over: Bio­gen, Ei­sai scrap big Alzheimer’s PhI­I­Is af­ter a pre­dictable BACE cat­a­stro­phe rais­es safe­ty fears

Months after analysts and investors called on Biogen and Eisai to scrap their BACE drug for Alzheimer’s and move on in the wake of a string of late-stage failures and rising safety fears, the partners have called it quits. And they said they were dropping the drug — elenbecestat — after the independent monitoring board raised concerns about…safety.

We don’t know exactly what researchers found in this latest catastrophe, but the companies noted in their release that investigators had determined that the drug was flunking the risk/benefit analysis.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

Mer­ck helps bankroll new part­ner Themis' game plan to fin­ish the chikun­gun­ya race and be­gin on­colyt­ic virus quest

As Themis gears up for a Phase III trial of its chikungunya vaccine, the Vienna-based biotech has closed out €40 million ($44 million) to foot the clinical and manufacturing bills.

Its heavyweight partners at Merck — which signed a pact around a mysterious “blockbuster indication” last month — jumped into the Series D, led by new investors Farallon Capital and Hadean Ventures. Adjuvant Capital also joined, as did current investors Global Health Investment Fund, aws Gruenderfonds, Omnes Capital, Ventech and Wellington Partners Life Sciences.